Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 10;10(9):661. doi: 10.1038/s41419-019-1874-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Pairwise comparison of the IndividCRS between HR-intact tumors and HR-defective tumors including those with a BRCA mutation, BRCA methylation, EMSY amplification, and defects in PTEN and FA genes. Significance was determined using the Wilcoxon rank-sum test. b Kaplan–Meier curves of OS for high IndividCRS HR-defective tumors and low IndividCRS HR-defective tumors versus HR-intact tumors. The high IndividCRS group of HR-defective tumors showed significantly improved OS, whereas low IndividCRS group of HR-defective tumors showed no significant difference in OS compared with HR-intact tumors. Significance was determined using the log-rank test. c Kaplan–Meier curves of OS for high IndividCRS BRCA-deficient tumors and low IndividCRS BRCA-deficient tumors versus BRCA1/2-intact tumors. The high IndividCRS group of BRCA-deficient tumors showed significantly improved OS, whereas low IndividCRS group of BRCA-deficient tumors showed no significant difference in OS compared with BRCA1/2-intact tumors. Significance was determined using the log-rank test. IndividCRS, individual chemotherapeutic response scores; HRD, homologous recombination deficiency; PTEN, phosphatase and tensin homolog; FA, Fanconi anemia; OS, overall survival